Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia

Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia

The Btk inhibitor ibrutinib has significantly changed the management of chronic lymphocytic leukemia (CLL) patients. Despite its clinical efficacy, relapses occur, and outcomes after ibrutinib failure are poor. Although BTK and PLCγ2 mutations have been found to be associated with ibrutinib resistan...

Full description

Bibliographic Details
Main Authors: Federica Frezzato, Andrea Visentin, Filippo Severin, Serena Pizzo, Edoardo Ruggeri, Nayla Mouawad, Leonardo Martinello, Elisa Pagnin, Valentina Trimarco, Alessia Tonini, Samuela Carraro, Stefano Pravato, Silvia Imbergamo, Sabrina Manni, Francesco Piazza, Anna Maria Brunati, Monica Facco, Livio Trentin
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cancers
Subjects:
chronic lymphocytic leukemia
Ibrutinib
HSP70
HSF1
drug-resistance
phenols
Online Access:https://www.mdpi.com/2072-6694/13/21/5453

Similar Items

Similar Items